Why are Medicare and Medicaid shown separately instead of combined?

They come from two different CMS data sources with no shared claim identifier, so they can't be reconciled into one number without double-counting or guessing. Every table and chart on this page keeps them fully separate.

Why is there no private/commercial revenue figure?

Private and commercial payer data comes from Transparency in Coverage files, which only publish negotiated rates — not claims or utilization volume. Without a volume figure, no revenue number can be computed for any provider from that data.

What does "Rank" mean in the Competitive Analysis & Benchmarks tables?

For a given CPT/HCPCS code, it's this provider's position by claims volume among all providers billing that same code at that geography level (State, National, or Iowa for Medicaid) — rank 1 means the highest claims volume for that code.

Why is the Medicaid comparison limited to Iowa only?

Medicaid is administered per-state with no single national fee schedule, so a state or national comparison the way Medicare has one isn't available. Iowa (this provider's own state) is the only grouping that's conceptually meaningful.

Why are the numbers rounded to the nearest 10?

To avoid implying more precision than the underlying data supports at a single-provider level. Ratios are kept precise since they're a relative comparison, not a volume or dollar figure.

How current is this data?

The Medicare and Medicaid tables are both single current snapshots, not refreshed on a recurring schedule yet.

Sreenath Kodali (NPI 1376823567)

Field	Value
Entity Type	Individual
Organization	Sreenath Kodali
Address	1111 Duff Ave
City	Ames
State	IA
ZIP	50010
Taxonomy	Hematology & Oncology Physician
NPI Enumerated	August 19, 2011

Payer Source	Total Paid
Medicare	$3.2M
Medicaid	$0

Key Findings

The provider’s billed population is effectively single‑payer Medicare: lifetime Medicare revenue is $3.2M while Medicaid revenue is none (no Medicaid billing on file). This concentration means analyses of utilization and financial exposure should be Medicare‑focused rather than split across payers.

Revenue is highly concentrated in a small set of drug infusions: the precomputed top‑3 Medicare codes account for 72.7% of this provider’s total Medicare revenue, with J9271 at $1.6M (51.0%), J9144 at $397.8K (12.9%), and J0897 at $271.1K (8.8%). Those three codes dominate the practice’s revenue mix and will drive most reimbursement risk and utilization trends.

The code mix and descriptors indicate an infusion‑centric hematology/oncology practice: high revenue and claim volumes for J9271 (pembrolizumab), J9144 (daratumumab), J0897 (denosumab), supported by chemotherapy administration codes such as 96413 and 96401 and cytotoxic drug codes like J9070 and J9041. This pattern is consistent with routine outpatient immunotherapy/chemotherapy administration and follow‑up oncology care rather than a procedure‑heavy surgical practice.

Competitive standing is uneven across key drugs: for pembrolizumab (J9271) the provider ranks #47 of 1841 nationally (97th percentile; notably above typical national volume), signaling top‑tier national volume for that drug; denosumab (J0897) ranks #535 of 10057 (95th percentile; notably above typical national volume), also well above peers; by contrast daratumumab (J9144) ranks #157 of 615 (74th percentile; typical, unremarkable volume), indicating a more ordinary position for that therapy. These ranks imply the provider is a major administrator of some high‑value immunotherapies while being more typical on others.

Office visit activity is unusually high relative to national peers: the provider reported 1.3K claims for 99214 ($123.5K, 4.0% of Medicare revenue) and 1.7K claims for 99213 ($106.1K, 3.4% of Medicare revenue); 99214 ranks #5132 of 479517 (99th percentile; extreme outlier, far above typical national volume for this code) and 99213 ranks #1435 of 457151 (100th percentile; extreme outlier, far above typical national volume for this code). This suggests substantial clinic throughput and routine follow‑up or management visits accompanying infusion services.

Several administration and supportive care codes show notably high percentile standing, reinforcing a high‑volume chemo/infusion operation: 96413 ranks #196 of 7514 (97th percentile; notably above typical national volume), J9070 (cyclophosphamide) ranks #7 of 135 (96th percentile; notably above typical national volume), and 96372 ranks #1180 of 58224 (98th percentile; notably above typical national volume). These high ranks across administration and drug codes point to sustained chemotherapy delivery capacity.

Operationally, the practice shows very large claim volumes with relatively low average paid per claim for many drug codes, consistent with unit/weight‑based or multi‑unit billing: examples include J9271 with 36.6K claims at $43 avg paid/claim and J1439 with 47.3K claims at $1 avg paid/claim. Those high claim counts imply high throughput and frequent, repeated administrations rather than occasional episodic treatments.

The provider’s NPI has been enumerated since 2011-08-19 (~15 years ago), indicating an established presence in the market. That tenure, combined with dominant Medicare infusion volumes for specific agents, suggests this practice is a mature outpatient oncology care site with entrenched Medicare billing patterns.

Medicare: Complete Services Breakdown

The CPT/HCPCS codes generating the most Medicare revenue for this provider.

86 rows

CPT/HCPCS Code	Description	Claims	Avg Paid	Revenue
J9271	Injection, pembrolizumab, 1 mg	36,600	$40	$1.6M
J9144	Injection, daratumumab, 10 mg and hyaluronidase‑fihj	11,700	$30	$397.8K
J0897	Injection, denosumab, 1 mg	15,060	$20	$271.1K
J1561	Injection, immune globulin, (gamunex-c/gammaked), non-lyophilized (e.g., liquid), 500 mg	4,480	$40	$165.8K
99214	The provider sees an established patient for an office visit or other outpatient visit involving evaluation and management. The visit involves a moderate level of medical decision making, and/or the…	1,340	$90	$123.5K
99213	The provider sees an established patient for an office visit or other outpatient visit involving evaluation and management. The visit involves a low level of medical decision making, and/or the…	1,710	$60	$106.1K
J0881	Injection, darbepoetin alfa, 1 microgram (non-esrd use)	40,420	$1	$80.8K
96413	Chemotherapy is a therapeutic procedure used for the treatment of cancer via the use of chemical agents. These chemical agents (drugs) work on the cancerous cells of the body to destroy them. These…	770	$90	$72.6K
J2506	Injection, pegfilgrastim, excludes biosimilar, 0.5 mg	890	$80	$71K
J1439	Injection, ferric carboxymaltose, 1 mg	47,250	$1	$47.3K

Showing 1–10 of 86

Medicare: Competitive Analysis & Benchmarks

How this provider's Medicare billing volume and revenue compare to other providers nationally and within its state, across 86 CPT/HCPCS codes.

View: State1 / 2

Claims Volume vs. Iowa Distribution

Sreenath Kodali — 9 of 25 codes billed far more than typical (above p95)

p5–p95 (all providers)p25–p75MedianThis providerOutlier

Rank Distribution — Iowa

Full comparison — all codes billed, vs. state median

86 rows

CPT/HCPCS Code	Rank	Provider Count	Median Claims	Avg Paid	Average Revenue
J9271	3	30	17,200	$40	$902.3K
J9144	3	10	9,900	$40	$476.8K
J1561	2	10	4,150	$40	$170.9K
J0897	6	190	1,920	$20	$74.1K
J0881	1	10	15,520	$1	$43.2K
J1439	5	10	41,250	$1	$39.7K
J2506	2	20	440	$80	$38.9K
96413	4	80	210	$90	$24K
J9217	36	50	140	$130	$23.4K
J9041	1	10	5,600	$1	$23.1K

Showing 1–10 of 86

Related Providers

Other providers that share a Tax Identification Number (TIN) with Sreenath Kodali, ranked by combined Medicare and Medicaid revenue.

Provider	State	Taxonomy	Medicare Revenue	Medicaid Revenue
Mcfarland Clinic PC	IA	Multi-Specialty Clinic/Center	$0	$26.7M
Thomas Buroker	IA	Medical Oncology Physician	$9.4M	$0
Kyle Alliman	IA	Ophthalmology Physician	$8.7M	$0
Alex Kartvelishvili	IA	Ophthalmology Physician	$8.1M	$0
Paul Boeke	IA	Ophthalmology Physician	$7.1M	$0
Austin Strohbehn	IA	Retina Specialist (Ophthalmology) Physician	$5.8M	$0
Jeremy Deutsch	KS	Hematology & Oncology Physician	$5.7M	$0
Robert Behrens	IA	Medical Oncology Physician	$5.2M	$0
Matthew Mcknight	IA	Foot & Ankle Surgery Podiatrist	$4.7M	$23.5K
James Singer	IA	Retina Specialist (Ophthalmology) Physician	$4.1M	$0

Nearby Providers

Other providers in the same ZIP code as Sreenath Kodali, ranked by combined Medicare and Medicaid revenue.

Provider	State	Taxonomy	Medicare Revenue	Medicaid Revenue
Mainstream Living, Inc.	IA	Social Worker	$0	$134.3M
Youth And Shelter Services, Inc.	IA	Counselor	$0	$11.4M
Mary Greeley Medical Center	IA	General Acute Care Hospital	$0	$9.1M
Mary Greeley Medical Center	IA	Land Ambulance	$0	$4.4M
Venkatesh Rudrapatna	IA	Hematology & Oncology Physician	$3.4M	$0
The Richmond Center	IA	Mental Health Counselor	$0	$2.4M
Sonam Patel	IA	Hematology & Oncology Physician	$1.8M	$0
Joseph Merchant	IA	Hematology & Oncology Physician	$1.8M	$0
Tracy Kangas	IA	Ophthalmology Physician	$1.1M	$0
Steven Anderson	IA	Ophthalmology Physician	$755.9K	$0

Sreenath Kodali — Billing Profile & Reimbursement Data

Sign up for Sreenath Kodali — Billing Profile & Reimbursement Data policy alerts

Sreenath Kodali — Billing Profile & Reimbursement Data

Sign up for Sreenath Kodali — Billing Profile & Reimbursement Data policy alerts

Key Findings

Medicare: Total Revenue Breakdown by CPT/HCPCS Code

Medicare: Complete Services Breakdown

Medicare: Competitive Analysis & Benchmarks

Related Providers

Nearby Providers

Frequently Asked Questions

References